Koen Augustyns

Prof. Dr. Koen Augustyns

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KJKoen Jansen
Koen Jansen
LHLeen Heirbaut
Leen Heirbaut
RVRobert Verkerk
Robert Verkerk
JCJonathan D. Cheng
Jonathan D. Cheng
JJJurgen Joossens
Jurgen Joossens
PVPieter Van Der Veken
Pieter Van Der Veken

26 September 2023 in Trends in Pharmacological Sciences
Verified
Journal Article
Open access
CSCamilla Scarpellini
Camilla Scarpellini
GKGreta Klejborowska
Greta Klejborowska
CLCaroline Lanthier
Caroline Lanthier
BHBehrouz Hassannia
Behrouz Hassannia
TBTom Vanden Berghe
Tom Vanden Berghe
KAKoen Augustyns
Koen Augustyns
Ferroptosis is an iron-catalysed form of regulated cell death, which is critically dependent on phospholipid peroxidation of cellular membranes. Ferrostatin 1 was one of the first synthetic radical-trapping antioxidants (RTAs) reported to block ferroptosis and it is widely used as reference compound. Ferroptosis has been linked to multiple diseases and the use of its inhibitors could have therapeutic potential. Although, novel biochemical pathways provide insights for different pharmacological targets, the use of lipophilic RTAs to block ferroptosis remains superior. In this Review, we provide a comprehensive overview of the different classes of ferroptosis inhibitors, focusing on endogenous and synthetic RTAs. A thorough analysis of their chemical, pharmacokinetic, and pharmacological properties and potential for in vivo use is provided.

25 March 2013 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
KJKoen Jansen
Koen Jansen
LHLeen Heirbaut
Leen Heirbaut
JCJonathan D. Cheng
Jonathan D. Cheng
JJJurgen Joossens
Jurgen Joossens
OROxana Ryabtsova
Oxana Ryabtsova
PVPieter Van Der Veken
Pieter Van Der Veken

1 August 2001 in Journal of Biological Chemistry
Verified
Journal Article
Open access
ALAnne-Marie Lambeir
Anne-Marie Lambeir
PPPaul Proost
Paul Proost
CDChristine Durinx
Christine Durinx
GBGunther Bal
Gunther Bal
KSKristel Senten
Kristel Senten
IMIngrid De Meester
Ingrid De Meester
Chemokines coordinate many aspects of leukocyte migration. As chemoattractants they play an important role in the innate and acquired immune response. There is good experimental evidence that N-terminal truncation by secreted or cell surface proteases is a way of modulating chemokine action. The localization of CD26/dipeptidyl peptidase IV on cell surfaces and in biological fluids, its primary specificity, and the type of naturally occurring truncated chemokines are consistent with such a function. We determined the steady-state catalytic parameters for a relevant selection of chemokines (CCL3b, CCL5, CCL11, CCL22, CXCL9, CXCL10, CXCL11, and CXCL12) previously reported to alter their chemotactic behavior due to CD26/dipeptidyl peptidase IV-catalyzed truncation. The results reveal a striking selectivity for stromal cell-derived factor-1alpha (CXCL12) and macrophage-derived chemokine (CCL22). The kinetic parameters support the hypothesis that CD26/dipeptidyl peptidase IV contributes to the degradation of certain chemokines in vivo. The data not only provide insight into the selectivity of the enzyme for specific chemokines, but they also contribute to the general understanding of CD26/dipeptidyl peptidase IV secondary substrate specificity.

28 April 2017 in Cell Death & Differentiation
Verified
Journal Article
Closed access
DRDiego Rojas-Rivera
Diego Rojas-Rivera
TDTinneke Delvaeye
Tinneke Delvaeye
RRRia Roelandt
Ria Roelandt
WNWim Nerinckx
Wim Nerinckx
KAKoen Augustyns
Koen Augustyns
MBMathieu J M Bertrand
Mathieu J M Bertrand

24 February 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
SCSamya Van Coillie
Samya Van Coillie
ESEmily Van San
Emily Van San
IGInes Goetschalckx
Ines Goetschalckx
BWBartosz Wiernicki
Bartosz Wiernicki
BMBanibrata Mukhopadhyay
Banibrata Mukhopadhyay
TBTom Vanden Berghe
Tom Vanden Berghe
The most common cause of death in the intensive care unit (ICU) is the development of multiorgan dysfunction syndrome (MODS). Besides life-supporting treatments, no cure exists, and its mechanisms are still poorly understood. Catalytic iron is associated with ICU mortality and is known to cause free radical-mediated cellular toxicity. It is thought to induce excessive lipid peroxidation, the main characteristic of an iron-dependent type of cell death conceptualized as ferroptosis. Here we show that the severity of multiorgan dysfunction and the probability of death are indeed associated with plasma catalytic iron and lipid peroxidation. Transgenic approaches underscore the role of ferroptosis in iron-induced multiorgan dysfunction. Blocking lipid peroxidation with our highly soluble ferrostatin-analogue protects mice from injury and death in experimental non-septic multiorgan dysfunction, but not in sepsis-induced multiorgan dysfunction. The limitations of the experimental mice models to mimic the complexity of clinical MODS warrant further preclinical testing. In conclusion, our data suggest ferroptosis targeting as possible treatment option for a stratifiable subset of MODS patients.